Prothena Corp Public PRTA
NASDAQ PRTA
$9.79 +0.19 (+1.98%)
As of: Sep 4, 2026 · 2:37 PM EDT

Prothena Corp Public (PRTA) Income towards Parent Company (2012 - 2026)

Prothena Corp Public (PRTA) posted quarterly Income towards Parent Company of $32.7 million for Q1 2026, up 154.36% year-over-year from $12.9 million in Q1 2025, and up 251.89% quarter-over-quarter from -$21.5 million in Q4 2025.

Analysis

Prothena Corp Public (PRTA) Income towards Parent Company (2012 - 2026) Analysis & Trends

Prothena Corp Public's Income towards Parent Company history runs 15 years deep, the most recent figure standing at $32.7 million for Q1 2026.

  • In Q1 2026, Income towards Parent Company rose 154.36% year-over-year to $32.7 million; the TTM figure through Mar 2026 stood at -$151.1 million (down 36.91% YoY), while the FY2025 annual figure was -$244.1 million, down 99.57% from the prior year.
  • Income towards Parent Company for Q1 2026 stood at $32.7 million, up from -$21.5 million in the prior quarter.
  • The five-year high for Income towards Parent Company was $66.8 million in Q2 2024, with the low at -$125.8 million in Q2 2025.
  • The 5-year median for Income towards Parent Company is -$45.7 million (2022), against an average of -$35.2 million.
  • The sharpest annual moves came in 2023 and 2024: Income towards Parent Company sank 1162.78% in 2023, then jumped 222.43% in 2024.
  • Prothena Corp Public's Income towards Parent Company stood at $6.3 million in 2022, then tumbled by 1162.78% to -$67.5 million in 2023, then increased by 14.07% to -$58.0 million in 2024, then surged by 62.85% to -$21.5 million in 2025, then soared by 251.89% to $32.7 million in 2026.
  • Business Quant data shows PRTA's Income towards Parent Company at $32.7 million in Q1 2026, -$21.5 million in Q4 2025, and -$36.5 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.74 Bn 130.89 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.52 Bn 77.52 Bn 3.93 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn
4 Moderna 58.04 Bn 52.91 Bn 52.00 Mn
5 Revolution Medicines 44.06 Bn 44.06 Bn -
6 BeOne Medicines 39.98 Bn 34.88 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.46 Bn 32.15 Bn 992.69 Mn
8 Royalty Pharma 28.41 Bn 27.57 Bn -
9 Insmed 27.44 Bn 26.28 Bn 358.27 Mn
10 Prothena Corp Public 510.50 Mn 222.30 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -18.58 Mn
Mar 31, 2026 32.72 Mn
Dec 31, 2025 -21.54 Mn
Sep 30, 2025 -36.51 Mn
Jun 30, 2025 -125.77 Mn
Mar 31, 2025 -60.17 Mn
Dec 31, 2024 -57.98 Mn
Sep 30, 2024 -59.00 Mn
Jun 30, 2024 66.89 Mn
Mar 31, 2024 -72.24 Mn
Dec 31, 2023 -67.48 Mn
Sep 30, 2023 21.92 Mn
Jun 30, 2023 -54.60 Mn
Mar 31, 2023 -46.86 Mn
Dec 31, 2022 6.30 Mn
Sep 30, 2022 -45.72 Mn
Jun 30, 2022 -41.24 Mn
Mar 31, 2022 -36.26 Mn
Dec 31, 2021 -33.14 Mn
Sep 30, 2021 109.25 Mn